# Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

> **NCT04915612** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine

## Key facts

- **NCT ID:** NCT04915612
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-21
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915612, "Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04915612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*